Form 4: Krystal Biotech Insider Sells Over $5.3 Million in Stock as 10b5-1 Plans Terminate

Krystal Biotech's President of R&D, Suma Krishnan, and her spouse have completed sales of company common stock totaling over $5.3 million through pre-arranged Rule 10b5-1 trading plans, which have now terminated.

Summary

• Suma Krishnan, President of R&D, Director, and 10% Owner of Krystal Biotech, Inc. (KRYS), reported sales of 18,000 shares of common stock between July 14 and July 16, 2025.
• These sales were executed at weighted average prices ranging from $150.00 to $151.79 per share, totaling approximately $2,705,732.18.
• Following these transactions, Suma Krishnan directly beneficially owns 1,438,711 shares of common stock.
• Additionally, Suma Krishnan's spouse, Krish S. Krishnan, sold 17,873 shares of common stock during the same period, at weighted average prices ranging from $150.00 to $151.79 per share, totaling approximately $2,687,975.63.
• These sales by both Suma Krishnan and her spouse were conducted pursuant to Rule 10b5-1 trading plans, which commenced on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock.
• Both Rule 10b5-1 trading plans have reached their maximum number of shares to be sold under such plans and have now terminated.
• Indirect beneficial ownership includes 90,000 shares by SMK Trust and 50,000 shares by Krishnan Family Trust, where the reporting person and her spouse are joint beneficial owners.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the fact that it was conducted under pre-arranged 10b5-1 plans and that these plans have now terminated mitigates significant negative sentiment. It's a planned liquidity event rather than a reaction to new adverse information.

Positives

• The termination of the Rule 10b5-1 trading plans removes a known, pre-scheduled selling pressure from the market, which could be viewed as a minor positive for stock stability.

Negatives

• Significant insider selling, even if pre-arranged, can sometimes be perceived negatively by investors as it represents a reduction in direct ownership by key management and large shareholders.
• The combined sales by the President of R&D and her spouse total over $5.3 million, representing a substantial divestment of shares.

Risks

• No specific new risks are introduced by this Form 4 filing beyond the general market perception of insider selling, which could potentially lead to short-term negative sentiment.

Future Outlook

The termination of the Rule 10b5-1 trading plans indicates that the pre-scheduled selling activity by the reporting person and her spouse under these specific plans has concluded, removing this particular source of future share sales.

Management Comments

• The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
• The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock.
• The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.

Industry Context

This Form 4 filing is specific to Krystal Biotech and its insider trading activities. While insider transactions are a common occurrence across all industries, these specific sales do not directly reflect broader industry trends or competitive dynamics within the biotechnology sector.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a standard mechanism used by corporate insiders to sell shares in a pre-arranged, compliant manner, mitigating concerns about trading on material non-public information. This aligns with common corporate governance practices for managing insider stock transactions.
• The reported sales amounts are significant in absolute terms, but without context of the insider's total wealth or the company's market capitalization, it is difficult to compare to specific peer company insider sales. However, the use of a 10b5-1 plan is a positive indicator of compliance and transparency compared to unscheduled open market sales.

Related Party Transactions

• Sales of common stock by Krish S. Krishnan, the spouse of the reporting person, are considered related party transactions.

Stakeholder Impact

• Shareholders: The sales represent a reduction in direct and indirect insider ownership, which could be interpreted differently by investors. However, the pre-arranged nature of the sales under a 10b5-1 plan typically lessens concerns about adverse implications.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• No further sales are expected under these specific Rule 10b5-1 plans as they have terminated. Any future sales by the reporting person or her spouse would require new disclosures.

Key Dates

Keywords

Krystal Biotech, KRYS, SEC Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Beneficial Ownership, Corporate Governance, Biotechnology